Markus Hartenbach
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Adipose triglyceride lipase driven lipolysis as a targetable metabolic vulnerability in prostate cancer with intrinsic metabolic inflexibility.
Journal: British journal of cancer
Published: August 23, 2025
PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 20, 2025
Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.
Journal: European journal of nuclear medicine and molecular imaging
Published: September 30, 2024
Preoperative detection of extraprostatic tumor extension in patients with primary prostate cancer utilizing [68Ga]Ga-PSMA-11 PET/MRI.
Journal: Insights into imaging
Published: July 17, 2024
A novel assessment of whole-mount Gleason grading in prostate cancer to identify candidates for radical prostatectomy: a machine learning-based multiomics study.
Journal: Theranostics
Published: April 03, 2024
Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: November 30, 2022
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: September 01, 2021
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 09, 2020
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.
Journal: International journal of cancer
Published: July 23, 2020
Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical nuclear medicine
Published: July 01, 2020
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 17, 2020
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 26, 2019
Last Updated: 09/26/2026